MorphoSys (MOR)
(Delayed Data from NSDQ)
$18.04 USD
-0.09 (-0.50%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.05 +0.01 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
MOR 18.04 -0.09(-0.50%)
Will MOR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MOR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MOR
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
MOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis (NVS) to Undertake Job Cuts in Development Department
Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
Other News for MOR
MorphoSys AG Announces Shift in Major Holdings
MorphoSys AG Sees Shift in Major Shareholders
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
MorphoSys AG Unveils Cancer Drug Trial Progress
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting